

## Table of Contents

<i>Chapter</i>	<i>Contents</i>	<i>Pg. No</i>
	List of Abbreviations	i-iv
	List of Figures	v-x
	List of Tables	xi-xii
<b>1</b>	<b>Introduction</b>	<b>1-33</b>
	<b>1.1 Emergence of Drug metabolism in Drug Discovery and Development</b>	
	1.1.1 Impact of globalization on pharmaceutical industry	1-2
	1.1.2 Drug metabolism in drug discovery and development	2-5
	1.1.3 Role of <i>in vitro</i> drug metabolism in preclinical drug development	6-7
	1.1.4 <i>In vivo</i> drug metabolism in preclinical drug development	7-8
	<b>1.2 Theoretical aspects of drug metabolism</b>	
	1.2.1 Hepatic Drug Metabolism	9
	1.2.2 End results of drug metabolism	9
	1.2.3 First Pass (Presystemic) Metabolism	9-11
	1.2.4 Classification of drug metabolism	11-13
	1.2.5 Role of cytochrome P450 (CYP P450) in drug metabolism	13-17
	1.2.6 Factors affecting drug metabolism	17-21
	<b>1.3 Malaria</b>	
	1.3.1 <i>Plasmodium falciparum</i> endemicity	22
	1.3.2 Antimalarial drug therapy	23
	1.3.3 Public Private Partnership (PPP) and the role of Medicines for Malaria Venture (MMV)	24-25
	1.3.4 Antimalarial drug discovery and development program at CDRI, Lucknow	25-26

Chapter	Content	Pg.No.
	1.4 Metabolism of endoperoxides	27-29
	1.5 Objectives	30-31
	References	32-34
2	<b>Preparation of Microsomes</b>	<b>35-48</b>
	2.1 Introduction	35-36
	2.2 Experimental	37-41
	2.2.1 Materials	37
	2.2.2 Animals	37
	2.2.3 Preparation of Buffer (Homogenization and Re-suspension)	38
	2.2.4 Sub-cellular fractionation	38
	2.2.5 Protein estimation	38-39
	2.2.6 Determination of Phenacetin-o-deethylase activity	39-41
	2.3 Results & discussions	41-47
	2.4 Conclusions	47
	References	48
3	<b>Determination of <i>in vitro</i> metabolic half life (<math>t_{1/2}</math>) and <i>in vitro</i> hepatic intrinsic clearance (<math>Cl_{int}</math>)</b>	<b>49-60</b>
	3.1 Introduction	49
	3.2 Experimental	49-54
	3.2.1 Materials	49
	3.2.2 Chromatographic Conditions	50
	3.2.3 Stock Solutions and Sample	50-51

Chapter	Contents	Pg.No.
	3.2.4 Sample Preparation	51
	3.2.5 Assay Validation	51
	3.2.6 Estimation of <i>in vitro</i> ( <i>t</i> <sub>1/2</sub> ) and <i>in vitro</i> hepatic <i>Clint</i>	52-54
	<b>3.3 Results and Discussion</b>	54-59
	<b>3.4 Conclusions</b>	59
	<b>References</b>	60
<b>4</b>	<b>Metabolite identification and structural elucidation</b>	<b>61-116</b>
	4.1 Introduction	61-62
	4.2 Experimental	62
	4.2.1 Materials	62
	4.2.2 Chromatographic conditions in HPLC-PDA and LCMS/MS	63
	4.2.3 Identification and structural elucidation of <i>in vitro</i> metabolites formed with rat liver microsomes	63-66
	4.2.4 Identification of <i>in vivo</i> metabolites in rat plasma	66
	4.2.5 Identification of <i>in vitro</i> metabolites formed with human liver microsomes	66
	<b>4.3 Results and discussions</b>	67-115
	<b>4.4 Conclusion</b>	115
	<b>References</b>	116
<b>5</b>	<b>Enzyme Kinetics</b>	<b>117-129</b>
	5.1 Introduction	117
	5.2 Experimental	118-122
	5.2.1 Materials	118
	5.2.2 Assay using substrate depletion approach	118-120

Chapter	Contents	Pg.No.
	5.2.3 Assay using product monitoring approach	120-122
	5.3 Results & discussions	122-127
	5.4 Conclusion	125
	References	128-129
6	<b>CYP Phenotyping</b>	<b>130-149</b>
	6.1 Introduction	130-131
	6.2 Experimental	132-135
	6.2.1 Materials	132
	6.2.2 Phenotyping using substrate depletion approach	132
	6.2.3 Phenotyping using product monitoring approach	132-133
	6.3 Docking of CDRI 99/411 with CYP 3A4	133-135
	6.4 Results & discussions	136-147
	6.5 Conclusion	147-148
	References	149
7	<b>Drug-Drug Interaction</b>	<b>150-170</b>
	7.1 Introduction	150
	7.2 Inhibition of CYPs	151-158
	7.2.1 Interactions involving inhibition	151-152
	7.2.2 Experimental	153-155
	7.2.2.1 Materials	153
	7.2.2.2 Determination of $IC_{50}$ of Lumefantrine and Piperaquine	153-155
	7.2.3 Results and discussions	155-157
	7.2.4 Conclusion	158

<b>Chapter</b>	<b>Contents</b>	<b>Pg.No.</b>
	<b>7.3 Induction of CYPs</b>	
	<b>7.3.1 Experimental</b>	159-169
	<b>7.3.1.1 Materials</b>	159-160
	<b>7.3.1.2 Primer designing</b>	160-161
	<b>7.3.1.3 Animals and treatment</b>	161
	<b>7.3.1.4 Isolation of total RNA</b>	162-163
	<b>7.3.1.5 Quantification of Total isolated RNA</b>	163
	<b>7.3.1.6 Agarose gel electrophoresis</b>	163-164
	<b>7.3.1.7 First strand cDNA synthesis</b>	164-165
	<b>7.3.1.8 Quantitative Real time PCR (qRT-PCR)</b>	165
	<b>7.3.2 Results and discussions</b>	166-169
	<b>7.3.3 Conclusions</b>	169
	<b>References</b>	170
	<b>Summary</b>	171-174

## List of Abbreviations

1-ABT	1-aminobenzotriazole
ACN	Acetonitrile
ACT	Artemisinin based combination therapy
ADME	Absorption, distribution, metabolism and elimination
AM	Absorption-Metabolism
amu	atomic Mass Unit
ATP	Adenosine triphosphate
Ahr	Aryl hydrocarbon receptor
AUC	Area under curve
AVID	Automation, Validation, Integration, Database Management
BSA	Bovine serum albumin
CAD	Collision activated dissociation
CAR	Constitutive androstane receptor
CC	Calibration Curve
CDRI	Central Drug Research Institute
CE	Collision Energy
CES	Collision Energy Spread
CID	Collision Induced Dissociation
Cl	Clearance
$C_{max}$	Maximum concentration
CS	Calibration standards
% C.V.	Coefficient of variation
CRO	Contract Research Organization
CYP450	Cytochrome P450
DDI	Drug Drug Interaction
DHA	Dihydroartemisinin
DMPK	Drug metabolism and pharmacokinetics
DP	Declustering Potential,
$EC_{50}$	concentration of substrate that gives a response half way between <i>Bottom</i> and <i>Top</i>
EMS	Enhanced mass scan

EPS	Enhanced product ion
ER	Enhanced resolution
ESI	Electro spray ionization
FAD	flavin adenine dinucleotide
FMN	Flavin mononucleotide
FMO	Flavin containing mono-oxygenases
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
GLP	Good laboratory Practice
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
HPLC-UV	High Performance Liquid Chromatography-UV Visible spectrophotometry
HTS	Highthroughput Screening
IAEC	Institutional Animal Ethics Committee
$IC_{50}$	concentration of inhibitor corresponding to a 50% decrease in reaction velocity compared to the control reaction
<i>in vitro</i> $t_{1/2}$	<i>in vitro</i> metabolic half life ( $t_{1/2}$ )
<i>in vitro</i> $Cl_{int}$	<i>in vitro</i> hepatic intrinsic clearance ( $Cl_{int}$ )
IPO	Initial Public Offering
IS	Internal standard
$K_m$	Michaelis-Menten constant for a substrate
LC-MS	Liquid Chromatography-Mass spectrometry
LC-MS/MS	Liquid Chromatography tandem mass spectrometry
LC-NMR	Liquid Chromatography nuclear magnetic resonance
LLOQ	Lower limit of quantification
LOD	Limit of detection
m/z	mass to charge ratio
MFO	mixed function oxygenase
mRNA	messenger Ribonucleic acid
MMV	Medicines for Malaria Venture
MRM	Multiple reaction monitoring
MS	Mass Spectrometry
NAD	$\beta$ -nicotinamide adenine dinucleotide

NADPH	Nicotinamide adenine dinucleotide phosphate hydrogen, reduced form
NCE	New chemical entity
NDA	New drug application
NDE	New drug entity
NIH	National Institute of Health
PAPS	3'-phosphoadenosine 5'-phosphosulfate
PCR	Polymerase Chain Reaction
PD	Pharmacodynamics
PDB	Protein Data Bank
PDA	Photo diode array detector
<i>Pf</i> API	<i>P.falciparum</i> annual parasite incidence
<i>Pf</i> PR	<i>P.falciparum</i> rate
PK	Pharmacokinetics
POC	Proof of Concept
POP	Proof of Principle
PPP	Public Private Partnership
PT	Pharmacological testing
PPAR $\alpha$	Peroxisome proliferator-activated receptor alpha
PXR	Pregnane X receptor
QA	Quality assurance
QC	Quality control
qRT-PCR	Quantitative Real Time Polymerase Chain Reaction
QHS	Qing-hao-su
HQC	High quality control
LQC	Low quality control
MQC	Medium quality control
rpm	revolutions per minute
R <sub>t</sub>	Retention time
% RSD	Percentage relative standard deviation
R&D	Research and Development
RNA	Ribonucleic acid
r	Pearson's correlation coefficient
[S]	Substrate concentration



S.D.	Standard deviation
S.E.	Standard Error
TDW	Triple distilled water
$T_{max}$	Time to reach $C_{max}$
UDPGA	Uridine diphosphate-glucuronic acid
UDP	Uridine diphosphate
UV	Ultra Violet
$v_0$	initial velocity
v/v	volume/volume
$V_{max}$	maximal initial reaction velocity
w/v	Weight /Volume

## List of figures

Fig No.	Title	Pg. No.
<b>Chapter 1</b>		
1.	Reasons for attrition in drug development	2
2.	A typical drug discovery testing scheme showing early assessment of ADME properties	3
3.	Role of drug metabolism in drug discovery and development	4
4.	AVID based HTS in preclinical drug metabolism	5
5.	Integrated use of <i>in vitro</i> metabolism models	7
6.	End results of drug metabolism	9
7.	The first pass metabolism of an orally dozed highly cleared drug showing removal of drug by gut and liver	10
8.	Percent contribution of individual CYP isoform in the metabolism of drugs	15
9.	Percent amount of individual P450 isoforms as determined by immunochemical methods in human liver microsomes	15
10.	Mechanism of CYP P450 mediated drug metabolism	17
11.	Factors affecting drug metabolism	18
12.	The spatial limits of <i>P. falciparum</i> malaria risk defined by PfAPI with further medical intelligence, temperature and aridity masks	22
13.	Collaborations of Medicines for Malaria Ventures in the world	25
14.	Chemical structure of CDRI 99/411	26
15.	Proposed biotransformation pathways for QHS (a) and DHA (b) <i>in vitro</i> and <i>in vivo</i>	28
16.	Structure of OZ277. Major metabolites (OZ397 and OZ381) were formed by the hydroxylation in the spiroadamantane ring.	29
<b>Chapter 2</b>		
1.	A generalized subcellular fractionation	35
2.	Standard curve of Net Absorbance at 595 nm versus BSA concentration	41

Fig.No.	Title	Pg.No.
3.	Product ion spectra of (a) paracetamol, (b) IS and (c) phenacetin	42
4.	Typical MRM chromatograms of paracetamol and IS in (a) rat blank liver microsome and (b) in rat liver microsome spiked with paracetamol and IS (c) after 0 minutes of incubation of Phenacetin and (d) after 30 minutes of incubation of Phenacetin	43-44
5.	Calibration standard curve of paracetamol	45
6.	Substrate saturation curve for CYP1A2 mediated phenacetin <i>o</i> -deethylase activity in in-house prepared rat liver microsomes. Each point in the curve represents the mean $\pm$ S.E. of the triplicate determinations.	47
<b>Chapter 3</b>		
1.	Chemical structure of CDRI 99/357 (IS)	50
2.	HPLC-PDA chromatograms of extracted blank and extracted QC high. The chromatographic conditions are written in the text.	55
3.	Depletion profile of CDRI 99/411 in (a) rat and (b) human liver microsomes (mean $\pm$ S.E. of triplicate experiments)	58
4.	<i>In vitro</i> hepatic intrinsic clearance in rat and human liver microsomes (mean $\pm$ S.E. $p > 0.05$ between rat and human).	59
<b>Chapter 4</b>		
1.	(a) HPLC-PDA chromatograms of metabolites (M1 and M2) of CDRI 99/411 and control (without drug and without NADPH) at 247 nm. (b) HPLC-PDA chromatograms of metabolites (M1 and M2) of CDRI 99/411 and CDRI 99/411 incubated with 1-ABT. The chromatographic conditions are given in the text.	67
2.	(a) HPLC-PDA overlaid chromatograms of M1, M2, M1 and M2 and blank acetonitrile. (b) Peak purity profile of M1 and (c) Peak purity profile of M2.	68-69
3.	The UV spectra of (a) CDRI 99/411 (b) M1 and (c) M2 obtained by HPLC-PDA	69-70
4.	Structure of ammonium adduct of CDRI 99/411	71

Fig.No.	Title	Pg.No.
5.	Enhanced Product Ion scan of ammonium adduct of CDRI 99/411	72
6.	Putative structures of main product ions of CDRI 99/411	73
7.	(a) Enhanced Product Ion and (b) MS <sup>3</sup> spectra of m/z 187.	74-75
8.	(a) Enhanced Product Ion and (b) MS <sup>3</sup> spectra of m/z 185.	75-76
9.	Proposed fragmentation of m/z 185 (Fragment A'), m/z 187(Fragment A'') and m/z 211 (Fragment B)	77
10.	Precursor Ion Scan of (a) m/z 103, (b) m/z 105, (c) 145, (d) 185 and (e) 187	78-80
11.	(a) Enhanced Product Ion and (b) Precursor Ion Scan of m/z 245	80-81
12.	Structure of characteristic ions of aromatic ring fragmentation	82
13.	(a) Enhanced Product Ion (b) MS <sup>3</sup> and (c) Precursor Ion Scan of m/z 227	83-84
14.	Enhanced Product Ion Scan of m/z 210	85
15.	Precursor Ion Scan of (a) m/z 151 and (b) m/z 167	85-86
16.	Hock type fragmentation (degradation) pathways under (a) neutral and (b) acid catalyzed conditions	86
17.	Schematic representation of fragmentation pattern of CDRI 99/411	87
18.	Incubation of CDRI 99/411 with rat liver microsomes. Typical MRM chromatograms of CDRI 99/411 (m/z 412.5 –m/z 185) and metabolites (m/z 428.5-m/z 201) in (a) Control without CDRI 99/411, (b) Control without NADPH, (c) CDRI 99/411 incubated with 1-ABT and (d) Test. The retention time of extracted ion chromatogram of CDRI 99/411 and metabolite (M1 and M2) were similar to that of HPLC-UV.	89-90
19.	Enhanced Product Ion scan of m/z 428.5 of isolated metabolites M1 and M2. Putative structures of fragments are depicted in the spectra.	92

Fig.No.	Title	Pg.No.
20.	Spectra of M1 and M2 showing (a) Enhanced Product Ion scan, (b) MS <sup>3</sup> scan and (c) Precursor ion scan of m/z 261	94-96
21.	Spectra of M1 and M2 showing (a) Enhanced Product Ion scan, (b) MS <sup>3</sup> scan and (c) Precursor ion scan of m/z 201	97-99
22.	Spectra of M1 and M2 showing (a) Enhanced Product Ion and (b) Precursor ion scan of m/z 203	100-101
23.	Precursor ion scan of m/z 183 of (a) M1 and (b) M2	102
24.	Spectra of M1 and M2 showing (a) Enhanced Product Ion and (b) Precursor ion scan of m/z 121	103-104
25.	Spectra of M1 and M2 showing (a) Enhanced Product Ion scan of m/z 119	105
26.	Precursor Ion Scan of m/z 151 of M1 and M2	106
27.	Schematic representation of fragmentation pattern of metabolites M1 and M2	107
28.	Scheme showing different hydroxylation pathways	109
29.	Proposed scheme for oxidative metabolism of CDRI 99/411	110
30.	Typical MRM chromatograms of CDRI 99/411 (m/z 412.5 – m/z 185) and metabolites (m/z 428.5-m/z 201) in (a) Plasma of Placebo (b) Plasma of CDRI 99/411 treated rats.	112
31.	Incubation of CDRI 99/411 with male human liver microsomes. Typical MRM chromatograms of CDRI 99/411 (m/z 412.5 -m/z 185) and metabolites (m/z 428.5-m/z 201) in (a) Control without CDRI 99/411, (b) Control without NADPH, (c) Test and (d) Enhanced Product Ion scan of m/z 428.5	113-115
<b>Chapter 5</b>		
1.	(a) Enzyme kinetics (Hill Plot). Each point in the curve represents the mean ± S.E. of triplicate determinations ( $p < 0.05$ between control and test) (b) Eadie-Hofstee Plot.	123

<b>Fig.No.</b>	<b>Title</b>	<b>Pg.No.</b>
2.	Typical MRM chromatogram of IS (m/z 406.6-m/z 179.3), metabolites (m/z 428.5-m/z 201) and CDRI 99/411 (m/z 412.5-m/z 185) in (a) rat blank liver microsome ,(b) CDRI 99/411 incubated with rat liver microsomes and (c) CDRI 99/411 incubated with human liver microsomes.	126
3.	Enzyme kinetics of CDRI 99/411 with rat (a & b) and human (c) liver microsomes. Each point in the curve represents the mean $\pm$ S.E. of triplicate determinations.	127
<b>Chapter 6</b>		
1.	Chemical structures of isomers (A and B) of (a) CDRI 99/411, (b) M1 and (c) M2.	134-135
2.	Identification of CYPs involved in the formation of metabolite M1 (a) and M2 (b) in rat.	138
3.	Identification of CYPs involved in the formation of metabolite M2 in human.	139
4.	CYP reaction phenotyping with rat liver microsomes. Typical MRM chromatograms of CDRI 99/411 (m/z 412.5 –m/z 185) and metabolites (m/z 428.5-m/z 201) in (a) Control without inhibitor, (b) inhibition with 1-Aminobenzotriazole (1-ABT), (c) inhibition with ketoconazole and (d) inhibition with troleandomycin	140-141
5.	CYP reaction phenotyping with human liver microsomes. Typical MRM chromatograms of CDRI 99/411 (m/z 412.5 – m/z 185) and metabolites (m/z 428.5-m/z 201) in (a) Control without inhibitor, (b) inhibition with 1-Aminobenzotriazole (1-ABT), (c) inhibition with ketoconazole and (d) inhibition with troleandomycin	142-143
6.	Binding mode of testosterone in the active site of CYP 3A4. Heme, proximal testosterone, distal testosterone and active site residues are shown in magenta, yellow, cyan, and green, respectively.	145
7.	Binding mode of CDRI 99/411 in the active site of CYP 3A4. Heme, CDRI 99/411 A, CDRI 99/411 B and active site residues are shown in pale green, magenta, cyan and green, respectively.	146

Fig.No.	Title	Pg.No.
	<b>Chapter 7</b>	
1.	Determination of $IC_{50}$ value with rat liver microsomes. Effect of Lumefrantine on the formation of regioisomer M1 (a) and M2 (b) in rat. Each bar represents the Mean $\pm$ S.E. of the triplicate determination.	156
2.	Determination of $IC_{50}$ value with human liver microsomes. Effect of Lumefrantine on the formation of regioisomer M2 in human. Each bar represents the Mean $\pm$ S.E. of the triplicate determination.	156
3.	Effect of Piperaquine on the formation of regioisomer M1 (a) and M2 (b) in rat. Each bar represents the Mean $\pm$ S.E. of the triplicate determination.	157
4.	Effect of Piperaquine on the formation of regioisomer M2 in human. Each bar represents the Mean $\pm$ S.E. of the triplicate determination.	157
5.	Total RNA isolated from CDRI 99/411, control and dexamethasone treated rat liver. The gel shows bands of 28S and 18S rRNA.	166
6.	Fold change in the expression of mRNA of hepatic CYPs and FMO1 in male Sprague Dawley rats treated with CDRI 99/411 (mean $\pm$ SD).	168
7.	Fold change in the expression of mRNA of hepatic CYPs and FMO1 in male Sprague Dawley rats treated with Dexamethasone (mean $\pm$ SD).	169

### List of Tables

Table No.	Title	Pg.No.
<b>Chapter 1</b>		
1.	Impact of globalization on pharmaceutical industry	1
2.	Potential issues encountered in Preclinical Drug Metabolism: <i>In vivo</i> studies with Animal models	8
3.	Characteristics of Phase I metabolism	12
4.	Characteristics of the Phase II metabolism	13
5.	Human CYP isoforms and their commonly used substrates, inhibitors and inducers.	16
6.	Differences in Important Cytochrome P450 Isoforms between Human and Rats.	19
7.	Important metabolising enzymes exhibiting polymorphism in humans	20
8.	Gender-Related differences in Cytochrome P450 expression in Rats.	20
9.	The effectiveness of antimalarial drugs limited by safety and resistance	24
<b>Chapter 2</b>		
1.	Sample preparation for the determination of protein concentration	39
2.	Assay conditions for CYP1A2 activity using Phenacetin-o-deethylation reaction	40
3.	Intra-day and inter-day accuracy and precision of Paracetamol in rat liver microsomes (n = 3 days with six replicates per day)	46
<b>Chapter 3</b>		
1.	Incubation milieu	52
2.	Summary of assay conditions used for the determination of metabolic stability CDRI 99/411 and testosterone	53



<b>Table No.</b>	<b>Title</b>	<b>Pg.No.</b>
3.	Intra-day and inter-day accuracy and precision and percentage recovery of CDRI 99/411 in rat liver microsomes (n = 3 days with six replicates per day)	56
<b>Chapter 4</b>		
1.	Experimental conditions for incubation and analysis of samples	64
<b>Chapter 5</b>		
1.	Assay conditions for the evaluation of enzyme kinetics of CDRI 99/411 using substrate depletion approach.	119
2.	Assay conditions for the evaluation of enzyme kinetics of CDRI 99/411 using product monitoring approach	121
<b>Chapter 6</b>		
1.	Human CYP isoforms and their specific inhibitors at potent concentrations	133
2.	Determination of CYP in the metabolism of CDRI 99/411	137
3.	Binding energies of isomers of CDRI 99/411 and their metabolites	147
<b>Chapter 7</b>		
1.	Assay conditions for the determination of $IC_{50}$ values of Lumefrantine and Piperaquine	154
2.	Forward and reverse primer sequences of rat liver drug metabolizing genes (specific for qRT-PCR)	161